AbbVie receives US antitrust approval for planned Pharmacyclics buyout
MLex Summary: AbbVie said Friday that the company has received US antitrust approval for its planned $21 billion acquisition of cancer drugmaker Pharmacyclics. The antitrust waiting period under the Hart-Scott-Rodino Act expired without...To view the full article, register now.
Already a subscriber? Click here to view full article